Atlas Venture Fund XI, L.P.'s Net Worth

$314 Million

Estimate Recalculated Sep 18, 2024 08:22PM EST

Who is Atlas Venture Fund XI, L.P.?

Atlas Venture Fund XI, L.P. has an estimated net worth of $314 Million. This is based on reported shares across multiple companies, which include Day One Biopharmaceuticals, Inc., Dyne Therapeutics, Inc., Akero Therapeutics, Inc., Ikena Oncology, Inc., Xilio Therapeutics, Inc., Third Harmonic Bio, Inc., and Korro Bio, Inc..

SEC CIK

Atlas Venture Fund XI, L.P.'s CIK is 0001708269

Past Insider Trading and Trends

2022 was Atlas Venture Fund XI, L.P.'s most active year for acquiring shares with 3 total transactions. Atlas Venture Fund XI, L.P.'s most active month to acquire stocks was the month of August. 2024 was Atlas Venture Fund XI, L.P.'s most active year for disposing of shares, totalling 18 transactions. Atlas Venture Fund XI, L.P.'s most active month to dispose stocks was the month of January. 2022 saw Atlas Venture Fund XI, L.P. paying a total of $5,100,000.00 for 7,366,470 shares, this is the most they've acquired in one year. In 2024 Atlas Venture Fund XI, L.P. cashed out on 1,631,865 shares for a total of $38,262,281.14, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Day One Biopharmaceuticals, Inc. (DAWN) Snapshot price: $13.5

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-9.09%
-600.85K
—
—
6.01M
Scheduled
Dec 12
Form 4
-8.33%
-600.85K
—
—
6.61M
Scheduled
Sep 19
Form 4
∞
766.67K
$15.00
$11,500,005.00
766.67K
Jun 17
Form 4
-10.00%
-801.14K
—
—
7.21M
Scheduled
Nov 24
Form 4
∞
9M
$16.00
$8,000,000.00
9M
Feb 1 - Jun 1
Form 3
—
0
—
—
0
No matching records found

Dyne Therapeutics, Inc. (DYN) Snapshot price: $33.03

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-5.89%
-807.84K
$24.32
-$19,626,902.97
12.9M
Scheduled
Feb 26 - Feb 28
Form 4
-5.35%
-500.79K
$22.68
-$11,339,780.44
8.86M
Scheduled
Feb 21 - Feb 23
Form 4
-6.96%
-510.15K
$23.26
-$11,867,292.26
6.82M
Scheduled
Feb 15 - Feb 20
Form 4
∞
934.58K
$10.70
$10,000,016.70
934.58K
Dec 12
Form 4
-10.00%
-814.01K
—
—
7.33M
Scheduled
Jul 13
Form 4
+361.95%
7.64M
—
—
9.75M
Sep 21
Form 3
—
0
—
—
0
No matching records found

Akero Therapeutics, Inc. (AKRO) Snapshot price: $26.41

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-8.24%
-242.88K
—
—
2.71M
Scheduled
Dec 31
Form 4
-14.36%
-570.97K
—
—
3.4M
Scheduled
Dec 17
Form 4
∞
3.97M
$16.00
—
3.97M
Jun 24
Form 3
—
0
—
—
0
No matching records found

Ikena Oncology, Inc. (IKNA) Snapshot price: $1.77

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+4.89%
98.72K
$15.34
$1,614,428.13
2.12M
Mar 30 - Dec 14
Form 4
+2,809.29%
4.75M
—
—
4.92M
Mar 30
Form 3
—
0
—
—
0
No matching records found

Xilio Therapeutics, Inc. (XLO) Snapshot price: $0.844

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-0.04%
-1.00K
$0.64
-$640.00
2.75M
Feb 8
Form 4
-0.15%
-4.24K
$0.85
-$3,600.45
2.76M
Jan 11 - Jan 12
Form 4
+10,385.82%
2.73M
$16.00
—
2.76M
Oct 26
Form 3
—
0
—
—
0
No matching records found